查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1808617

罕见疾病诊断市场（按检测类型、技术、疾病类型和最终用户划分）—2025-2030 年全球预测

Rare Disease Diagnostics Market by Test type, Technology, Disease Type, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2024年罕见疾病诊断市场价值为27.5亿美元，预计2025年将成长至30.2亿美元，复合年增长率为10.06%，到2030年将达到49亿美元。

主要市场统计数据
基准年2024年 27.5亿美元
预计2025年 30.2亿美元
预测年份 2030 49亿美元
复合年增长率（%） 10.06%

强调准确的罕见疾病诊断在改善患者预后和製定未来医疗保健策略方面的关键作用

罕见疾病诊断是现代医疗保健领域最具挑战性但回报丰厚的前沿领域之一，需要精准、敏捷和协作。这些疾病通常症状隐匿或不典型，难以透过常规诊断途径确诊。因此，及时准确的诊断至关重要，这不仅对于启动改变生活的治疗至关重要，也有助于减轻患者及其家属的情绪和经济负担。

分析重新定义罕见疾病诊断方法并加快准确发现时间的技术和监管变化

在技​​术突破和监管格局不断演变的推动下，罕见疾病诊断领域正在经历重大变革。实验室正在从单基因检测转型到结合基因组学、蛋白质组学和代谢体学数据流的综合多体学平台。这项转变使临床医生能够从症状评估转向分子诊断，并最终制定标靶治疗。

评估 2025 年美国关税改革对罕见疾病诊断供应链和成本结构模式的影响

2025年美国关税改革的实施，将对罕见疾病诊断供应链产生显着波动，影响成本结构与策略采购决策。关键试剂、客製化检测套组和专用设备的进口关税，为努力维持服务可负担性和营运灵活性的製造商和实验室带来了额外的复杂性。

从测试类型、技术疾病类型和最终用户细分领域发掘洞察，推动罕见疾病诊断的策略重点

透过多种细分视角来区分罕见疾病诊断市场，有助于揭示当前的动态和新兴机会。从检测类型（生化、遗传、组织病理学、免疫学和分子方法）的角度来看，每个领域都针对不同的临床需求。生化检测仍是代谢失调的第一线筛检，而标靶基因检测则为单基因疾病提供了明确的确诊依据。组织病理学检测对于某些肿瘤和免疫疾病仍然至关重要，而免疫测量则可以快速洞察自体免疫特征。分子技术具有较高的敏感度和特异性，尤其适用于需要多重检测的疾病。

探索美洲、欧洲、中东和非洲以及亚太地区的区域动态，以确定罕见疾病诊断领域的成长机会

了解区域动态对于制定充分利用该地区优势并应对其独特挑战的策略至关重要。在美洲，先进的医疗基础设施、健全的报销体系和强劲的资本市场支援尖端诊断技术的快速应用。学术中心和私人企业之间的合作网络进一步加速了转化研究和临床检验。

确定在罕见疾病诊断领域塑造创新伙伴关係和竞争策略的关键产业参与者

一群先驱企业正在透过研发策略投资、全球扩张和合资企业，塑造罕见疾病诊断生态系统。产业领导者正在扩展产品系列，纳入融合高解析度定序、自动化样本处理和先进生物资讯学的整合平台。这些全面的解决方案简化了实验室工作流程，同时以前所未有的速度提供临床可操作的见解。

为行业领导者提供切实可行的建议，以加强合作、利用新技术并优化罕见疾病诊断结果

致力于加速罕见疾病诊断技术进步的产业领导者应采取多管齐下的策略，并专注于协作、技术应用和相关人员的参与。与学术中心、病患权益团体和政府机构建立跨部门合作伙伴关係，可以整合分散的专业知识，并就标准化通讯协定达成共识。

详细的调查方法，阐明了支持罕见疾病诊断见解的数据收集和分析框架以及检验过程

该调查方法整合了一套全面的研究方法，旨在确保严谨性、透明度和可操作性。原始数据是透过与诊断实验室、医院系统、监管机构和患者权益组织的顶尖专家进行深入访谈收集的。这些对话就未满足的需求、技术应用挑战以及监管考量提供了细緻的观点。

摘要核心发现的令人信服的结论；提高罕见疾病诊断能力的产业影响和策略挑战

摘要：罕见疾病诊断是科学创新与病人影响的交会点，受先进技术、不断发展的法规和协作生态系统的驱动。細項分析揭示了有针对性的成长路径，而区域洞察则凸显了利用基础设施优势和解决特定障碍的区域策略的重要性。

目录

第一章：前言

第二章调查方法

第三章执行摘要

第四章 市场概况

第五章市场动态

  • 对罕见遗传疾病的早期和准确诊断的需求日益增长
  • 基因组和分子诊断平台的技术进步
  • 分散式即时基因检测的出现，为偏远地区快速诊断
  • 采用蛋白质体学和代谢体学相结合的多体学方法发现罕见疾病生物标记
  • 生技公司加大对罕见疾病研究和诊断的投资
  • 加强罕见疾病诊断的监管支持和政策倡议
  • 提高患者群体和医疗保健提供者的意识提升和倡导
  • 全EXOME和全基因定序在临床上的应用日益增多
  • 将人工智慧融入罕见疾病诊断工作流程，提高检测准确性
  • 液态生物检体技术在罕见癌症诊断和治疗反应监测中的应用日益广泛

第六章 市场洞察

  • 波特五力分析
  • PESTEL分析

第七章 2025年美国关税的累积影响

第 8 章：罕见疾病诊断市场（按测试类型）

  • 生物化学检验
  • 基因检测
  • 组织病理学检查
  • 免疫学检测
  • 分子检测

9. 罕见疾病诊断市场（依技术）

  • 萤光原位杂合反应（FISH）
  • 质谱法
  • 次世代定序（NGS）
  • 聚合酵素链锁反应（PCR）
  • 桑格定序
  • 全EXOME定序
  • 全基因组序列分析

第 10 章罕见疾病诊断市场（依疾病类型）

  • 心血管疾病
  • 血液疾病
  • 免疫疾病
  • 代谢紊乱
  • 神经系统疾病
  • 肿瘤疾病
  • 呼吸系统疾病

第 11 章罕见疾病诊断市场（按最终用户）

  • 诊断实验室
  • 医院和诊所
  • 研究机构和CRO

12.美洲罕见疾病诊断市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 阿根廷

13. 欧洲、中东和非洲罕见疾病诊断市场

  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 阿拉伯聯合大公国
  • 沙乌地阿拉伯
  • 南非
  • 丹麦
  • 荷兰
  • 卡达
  • 芬兰
  • 瑞典
  • 奈及利亚
  • 埃及
  • 土耳其
  • 以色列
  • 挪威
  • 波兰
  • 瑞士

14. 亚太地区罕见疾病诊断市场

  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国
  • 印尼
  • 泰国
  • 菲律宾
  • 马来西亚
  • 新加坡
  • 越南
  • 台湾

第十五章 竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争分析
    • Novartis AG
    • F. Hoffmann-La Roche Ltd.
    • Pfizer Inc.
    • 23andMe Inc.
    • 3billion, Inc.
    • Agilent Technologies Inc.
    • ARCHIMED Life Science GmbH
    • ARUP Laboratories
    • AstraZeneca PLC
    • Azenta Life Sciences
    • Baylor Genetics
    • Caris Life Sciences
    • CENTOGENE NV
    • Eurofins Scientific Inc.
    • Fulgent Genetics, Inc.
    • Illumina, Inc.
    • Invitae Corporation
    • MedGenome Labs Ltd
    • OPKO Health, Inc.
    • Quest Diagnostics Incorporated
    • Thermo Fisher Scientific Inc.
    • Sanofi SA
    • Travere Therapeutics Inc.
    • Ambry Genetics
    • Bio-Rad Laboratories
    • Centogene AG

第十六章 研究人工智慧

第十七章 研究统计

第十八章 研究联络人

第十九章 研究报导

第二十章 附录

Product Code: MRR-5C6F41F5B034

The Rare Disease Diagnostics Market was valued at USD 2.75 billion in 2024 and is projected to grow to USD 3.02 billion in 2025, with a CAGR of 10.06%, reaching USD 4.90 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 2.75 billion
Estimated Year [2025] USD 3.02 billion
Forecast Year [2030] USD 4.90 billion
CAGR (%) 10.06%

Introduction Highlighting the Critical Role of Precise Rare Disease Diagnostics in Improving Patient Outcomes and Shaping Future Healthcare Strategies

Rare disease diagnostics represent one of the most challenging yet rewarding frontiers in modern healthcare, demanding precision, agility, and collaboration. These conditions often present with subtle or atypical symptoms that can elude standard diagnostic pathways. As such, timely and accurate identification is essential not only for initiating life-altering treatment but also for alleviating the emotional and financial burden experienced by patients and their families.

Over the past decade, advances in both laboratory science and digital technologies have transformed our ability to detect and characterize rare conditions. Next-generation sequencing and advanced imaging modalities now offer unprecedented resolution and throughput, while integrated data platforms facilitate deeper insights into genotype-phenotype correlations. In parallel, patient registries and real-world evidence networks fuel longitudinal studies that validate diagnostic algorithms and enhance our understanding of natural histories.

Looking ahead, the importance of rare disease diagnostics will only intensify as personalized medicine gains traction. Precision-driven approaches require not just isolated tests but cohesive diagnostic ecosystems that integrate modular platforms with artificial intelligence and machine learning to refine clinical decision support. These convergent trends underscore the critical role of diagnostics in shaping the future of healthcare strategy and underscore the urgent need for stakeholders to align around a common vision for innovation, efficiency, and patient impact.

Analyzing the Transformative Technological and Regulatory Shifts Redefining Rare Disease Diagnostic Approaches and Accelerating Time to Accurate Detection

The landscape of rare disease diagnostics is undergoing a profound metamorphosis driven by converging technological breakthroughs and evolving regulatory frameworks. Laboratories are transitioning from single-gene assays to comprehensive multi-omics platforms that combine genomic, proteomic, and metabolomic data streams. This shift enables clinicians to move beyond symptomatic assessments and toward molecularly informed diagnoses that can be linked to targeted therapies.

Simultaneously, regulatory agencies are streamlining pathways for breakthrough diagnostics, offering expedited review processes and adaptive protocols that prioritize rapid patient access. Harmonization efforts across jurisdictions are reducing duplicative documentation requirements, fostering global trials, and encouraging collaborative validation studies. As a result, diagnostic developers can navigate complex regulatory environments with greater predictability and speed.

Digital health innovations are further amplifying these transformative shifts. Cloud-based bioinformatics pipelines, decentralized clinical trial models, and telepathology solutions break down geographical barriers, enabling expert interpretation of complex rare disease profiles irrespective of patient location. Collectively, these trends are redefining how diagnostics are designed, validated, and deployed, ultimately accelerating the journey from discovery to clinical application and paving the way for a new era of precision healthcare.

Assessing the Impact of United States Tariff Changes in 2025 on the Landscape of Rare Disease Diagnostics Supply Chains and Cost Structures

The implementation of revised United States tariffs in 2025 has generated notable reverberations throughout the rare disease diagnostics supply chain, influencing both cost structures and strategic sourcing decisions. Import duties on key reagents, custom test kits, and specialized instrumentation have introduced additional layers of complexity for manufacturers and laboratories striving to maintain service affordability and operational flexibility.

In response, organizations are reevaluating supplier portfolios, seeking to diversify procurement channels and establish regional manufacturing hubs that mitigate exposure to fluctuating tariff schedules. Some diagnostic developers have accelerated partnerships with domestic component producers to secure preferential trade classifications and optimize landed costs. Meanwhile, distributors are renegotiating supply contracts to incorporate tariff escalation clauses, protecting margins while preserving service continuity for end users.

Despite the initial cost pressures, these adjustments have also spurred innovation in reagent formulation and assay consolidation. By engineering multi-analyte platforms that maximize throughput from a single sample input, laboratories can offset incremental duties through enhanced efficiency gains. Moreover, the tariff environment has underscored the strategic importance of proactive policy engagement and trade advocacy, empowering stakeholders to shape future tariff reviews and ensure sustainable access to cutting-edge diagnostic technologies.

Unveiling Insights from Test Type Technology Disease Type and End-User Segmentations to Drive Strategic Priorities in Rare Disease Diagnostics

Differentiating the rare disease diagnostics market through multiple segmentation lenses provides clarity around both current dynamics and emerging opportunities. When viewed through the prism of test type-which encompasses biochemical, genetic, histopathological, immunological, and molecular approaches-it becomes evident that each modality addresses distinct clinical imperatives. Biochemical assays continue to serve as frontline screens for metabolic disorders, while targeted genetic tests offer definitive confirmation of monogenic conditions. Histopathological evaluations remain indispensable for certain oncological and immunological disorders, and immunoassays provide rapid insights into autoimmune profiles. Molecular techniques deliver high sensitivity and specificity, especially for conditions requiring multiplexed detection.

Examining the market by technology-ranging from fluorescence in situ hybridization and mass spectrometry to advanced sequencing applications like next-generation, Sanger, whole exome, and whole genome sequencing-reveals an accelerating shift toward high-throughput platforms. These technologies facilitate comprehensive variant calling and enable the discovery of novel biomarkers.

Segmenting by disease type, from cardiovascular and neurological disorders to hematological, immunological, metabolic, oncological, and respiratory conditions, highlights the differential adoption rates and unmet needs within each therapeutic area. Furthermore, analyzing end-user categories-including diagnostic laboratories, hospitals and clinics, and research laboratories and contract research organizations-uncovers varying levels of investment in specialized instrumentation and data analytics capabilities. Together, these segmentation insights illuminate targeted pathways for market entry, resource allocation, and technology deployment.

Exploring Regional Dynamics across the Americas Europe Middle East Africa and Asia Pacific to Identify Growth Opportunities in Rare Disease Diagnostics

Understanding regional dynamics is essential for tailoring strategies that harness local strengths and address unique challenges. In the Americas, advanced healthcare infrastructure, robust reimbursement frameworks, and deep capital markets support rapid adoption of cutting-edge diagnostics. Collaborative networks between academic centers and commercial entities further accelerate translational research and clinical validation.

In Europe, Middle East and Africa, diverse regulatory landscapes coexist with ambitious initiatives aimed at harmonizing diagnostic standards across national borders. Pan-regional consortia facilitate shared access to biobanks and patient registries, while public-private partnerships have emerged to fund innovative assay development. Conversely, certain markets within the Middle East and Africa face infrastructure and training constraints that require targeted capacity-building investments.

Across Asia Pacific, government-led programs are driving domestic manufacturing of diagnostic reagents and instruments, complemented by widespread adoption of digital health solutions. Telemedicine platforms and remote interpretation services are bridging gaps in specialist availability, particularly in emerging markets. Strategic alliances between local companies and global technology providers are expanding the reach of advanced testing capabilities, while at the same time fostering regulatory knowledge transfer and workforce development.

Identifying Key Industry Players Shaping Innovation Partnerships and Competitive Strategies within the Rare Disease Diagnostics Sector

A cadre of pioneering companies is shaping the rare disease diagnostics ecosystem through strategic investments in research and development, global expansion, and collaborative ventures. Industry leaders are extending their product portfolios to encompass integrated platforms that combine high-resolution sequencing with automated sample processing and advanced bioinformatics. These holistic solutions streamline laboratory workflows while delivering clinically actionable insights with unprecedented speed.

Emerging players are carving out niches by focusing on bespoke assay development for ultra-rare conditions or leveraging artificial intelligence to interpret complex genomic datasets. Partnerships between diagnostic innovators and pharmaceutical firms are enabling companion diagnostic programs that align test development with therapeutic pipelines. Meanwhile, alliances with academic institutions and patient advocacy groups are fueling co-creation models that ensure diagnostic designs resonate with real-world clinical needs.

Competitive differentiation is increasingly driven by vertical integration, whereby stakeholders control multiple stages of the value chain-from reagent synthesis through data analytics and result interpretation. As a result, the most successful organizations are those that can orchestrate cross-functional teams to deliver end-to-end diagnostic services, fostering sustained leadership in the rapidly evolving rare disease diagnostics sector.

Actionable Recommendations for Industry Leaders to Enhance Collaboration Leverage Emerging Technologies and Optimize Rare Disease Diagnostic Outcomes

Industry leaders seeking to accelerate progress in rare disease diagnostics should embrace a multifaceted strategy focused on collaboration, technology adoption, and stakeholder engagement. Establishing cross-sector alliances with academic centers, patient advocacy organizations, and government agencies will unify fragmented expertise and drive consensus on standardized protocols.

Investing in modular, scalable platforms that accommodate both targeted panels and broad-spectrum analyses will ensure flexibility to address diverse clinical scenarios. Simultaneously, integrating artificial intelligence and machine learning into diagnostic pipelines can optimize data interpretation, reduce turnaround times, and enhance diagnostic confidence.

Engaging proactively with payers and regulatory bodies through value demonstration studies and real-world evidence generation will facilitate favorable reimbursement and approval pathways. Strengthening supply chain resilience by diversifying suppliers and building regional manufacturing capabilities can mitigate the impact of trade fluctuations. Finally, cultivating a patient-centric approach-incorporating patient feedback loops and transparent communication-will foster trust and improve uptake of novel diagnostic solutions.

Detailed Research Methodology Demonstrating Data Collection Analytical Frameworks and Validation Processes Underpinning Rare Disease Diagnostics Insights

This research integrates a comprehensive methodology designed to ensure rigor, transparency, and actionable insight. Primary data was collected through in-depth interviews with leading experts across diagnostic laboratories, hospital systems, regulatory agencies, and patient advocacy groups. These conversations provided nuanced perspectives on unmet clinical needs, technology adoption challenges, and regulatory considerations.

Secondary research encompassed an extensive review of peer-reviewed literature, clinical trial registries, patent filings, and governmental policy documents to validate emerging trends and technological breakthroughs. Publicly available financial reports and corporate disclosures were analyzed to track strategic investments, partnerships, and market entry activities.

A structured analytical framework was applied to triangulate qualitative insights with quantitative data, facilitating a balanced evaluation of market dynamics. Key findings underwent peer review by an internal advisory board, ensuring methodological consistency and eliminating bias. The resulting report offers a robust foundation for strategic decision-making, combining empirical evidence with expert interpretation.

Compelling Conclusion Summarizing Core Insights Industry Implications and Strategic Imperatives for Advancing Rare Disease Diagnostic Capabilities

In summary, rare disease diagnostics stands at the nexus of scientific innovation and patient impact, driven by advanced technologies, regulatory evolution, and collaborative ecosystems. Segmentation analysis reveals targeted pathways for growth, while regional insights underscore the importance of localized strategies that leverage infrastructure strengths and address specific barriers.

The recalibration of supply chains in response to tariff adjustments highlights both the vulnerabilities and the resilience of the diagnostics ecosystem. Industry leaders and emerging players alike must adopt agile business models that integrate scalable platforms, artificial intelligence, and patient-centric design to maintain a competitive edge.

By implementing the actionable recommendations outlined herein-fostering cross-sector collaborations, engaging proactively with stakeholders, and investing in modular technologies-organizations can enhance diagnostic precision, reduce time to diagnosis, and ultimately transform the patient journey. The collective pursuit of these strategic imperatives will accelerate the realization of a truly precision-driven era in rare disease diagnostics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Market Sizing & Forecasting

5. Market Dynamics

  • 5.1. Growing demand for early and accurate diagnosis of rare genetic disorders
  • 5.2. Technological advancements in genomic and molecular diagnostic platforms
  • 5.3. Emergence of decentralized point-of-care genetic testing for rapid diagnosis in remote communities
  • 5.4. Adoption of multiomics approaches combining proteomics and metabolomics in rare disease biomarker discovery
  • 5.5. Rising investment by biotechnology companies in rare disease research and diagnostics
  • 5.6. Enhanced regulatory support and policy initiatives for orphan disease diagnostics
  • 5.7. Rising awareness and advocacy efforts among patient communities and healthcare providers
  • 5.8. Growing implementation of whole exome and whole genome sequencing in clinical settings
  • 5.9. Integration of artificial intelligence in rare disease diagnostic workflows to enhance detection accuracy
  • 5.10. Increasing utilization of liquid biopsy techniques in monitoring treatment response in rare cancer diagnostics

6. Market Insights

  • 6.1. Porter's Five Forces Analysis
  • 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Rare Disease Diagnostics Market, by Test type

  • 8.1. Introduction
  • 8.2. Biochemical Tests
  • 8.3. Genetic Tests
  • 8.4. Histopathological Tests
  • 8.5. Immunological Tests
  • 8.6. Molecular Tests

9. Rare Disease Diagnostics Market, by Technology

  • 9.1. Introduction
  • 9.2. Fluorescence in situ Hybridization (FISH)
  • 9.3. Mass Spectrometry
  • 9.4. Next-Generation Sequencing (NGS)
  • 9.5. Polymerase Chain Reaction (PCR)
  • 9.6. Sanger Sequencing
  • 9.7. Whole Exome Sequencing
  • 9.8. Whole Genome Sequencing

10. Rare Disease Diagnostics Market, by Disease Type

  • 10.1. Introduction
  • 10.2. Cardiovascular Disorders
  • 10.3. Hematological Disorders
  • 10.4. Immunological Disorders
  • 10.5. Metabolic Disorders
  • 10.6. Neurological Disorders
  • 10.7. Oncological Disorders
  • 10.8. Respiratory Disorders

11. Rare Disease Diagnostics Market, by End-User

  • 11.1. Introduction
  • 11.2. Diagnostic Laboratories
  • 11.3. Hospitals & Clinics
  • 11.4. Research Laboratories & CROs

12. Americas Rare Disease Diagnostics Market

  • 12.1. Introduction
  • 12.2. United States
  • 12.3. Canada
  • 12.4. Mexico
  • 12.5. Brazil
  • 12.6. Argentina

13. Europe, Middle East & Africa Rare Disease Diagnostics Market

  • 13.1. Introduction
  • 13.2. United Kingdom
  • 13.3. Germany
  • 13.4. France
  • 13.5. Russia
  • 13.6. Italy
  • 13.7. Spain
  • 13.8. United Arab Emirates
  • 13.9. Saudi Arabia
  • 13.10. South Africa
  • 13.11. Denmark
  • 13.12. Netherlands
  • 13.13. Qatar
  • 13.14. Finland
  • 13.15. Sweden
  • 13.16. Nigeria
  • 13.17. Egypt
  • 13.18. Turkey
  • 13.19. Israel
  • 13.20. Norway
  • 13.21. Poland
  • 13.22. Switzerland

14. Asia-Pacific Rare Disease Diagnostics Market

  • 14.1. Introduction
  • 14.2. China
  • 14.3. India
  • 14.4. Japan
  • 14.5. Australia
  • 14.6. South Korea
  • 14.7. Indonesia
  • 14.8. Thailand
  • 14.9. Philippines
  • 14.10. Malaysia
  • 14.11. Singapore
  • 14.12. Vietnam
  • 14.13. Taiwan

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Novartis AG
    • 15.3.2. F. Hoffmann-La Roche Ltd.
    • 15.3.3. Pfizer Inc.
    • 15.3.4. 23andMe Inc.
    • 15.3.5. 3billion, Inc.
    • 15.3.6. Agilent Technologies Inc.
    • 15.3.7. ARCHIMED Life Science GmbH
    • 15.3.8. ARUP Laboratories
    • 15.3.9. AstraZeneca PLC
    • 15.3.10. Azenta Life Sciences
    • 15.3.11. Baylor Genetics
    • 15.3.12. Caris Life Sciences
    • 15.3.13. CENTOGENE N.V.
    • 15.3.14. Eurofins Scientific Inc.
    • 15.3.15. Fulgent Genetics, Inc.
    • 15.3.16. Illumina, Inc.
    • 15.3.17. Invitae Corporation
    • 15.3.18. MedGenome Labs Ltd
    • 15.3.19. OPKO Health, Inc.
    • 15.3.20. Quest Diagnostics Incorporated
    • 15.3.21. Thermo Fisher Scientific Inc.
    • 15.3.22. Sanofi S.A.
    • 15.3.23. Travere Therapeutics Inc.
    • 15.3.24. Ambry Genetics
    • 15.3.25. Bio-Rad Laboratories
    • 15.3.26. Centogene AG

16. ResearchAI

17. ResearchStatistics

18. ResearchContacts

19. ResearchArticles

20. Appendix

LIST OF FIGURES

  • FIGURE 1. RARE DISEASE DIAGNOSTICS MARKET RESEARCH PROCESS
  • FIGURE 2. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 3. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 4. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 6. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 8. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 10. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 12. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 14. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 16. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 21. RARE DISEASE DIAGNOSTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 22. RARE DISEASE DIAGNOSTICS MARKET, FPNV POSITIONING MATRIX, 2024
  • FIGURE 23. RARE DISEASE DIAGNOSTICS MARKET: RESEARCHAI
  • FIGURE 24. RARE DISEASE DIAGNOSTICS MARKET: RESEARCHSTATISTICS
  • FIGURE 25. RARE DISEASE DIAGNOSTICS MARKET: RESEARCHCONTACTS
  • FIGURE 26. RARE DISEASE DIAGNOSTICS MARKET: RESEARCHARTICLES

LIST OF TABLES

  • TABLE 1. RARE DISEASE DIAGNOSTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, 2025-2030 (USD MILLION)
  • TABLE 5. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 7. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 9. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 11. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY BIOCHEMICAL TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 13. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY GENETIC TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 15. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HISTOPATHOLOGICAL TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 17. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 19. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MOLECULAR TESTS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 21. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 23. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY FLUORESCENCE IN SITU HYBRIDIZATION (FISH), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 25. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY MASS SPECTROMETRY, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 27. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEXT-GENERATION SEQUENCING (NGS), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 29. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY POLYMERASE CHAIN REACTION (PCR), BY REGION, 2025-2030 (USD MILLION)
  • TABLE 31. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY SANGER SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 33. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE EXOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 35. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY WHOLE GENOME SEQUENCING, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 37. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 39. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY CARDIOVASCULAR DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 41. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HEMATOLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 43. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY IMMUNOLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 45. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 47. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 49. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY ONCOLOGICAL DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 51. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESPIRATORY DISORDERS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 53. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 55. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 57. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 59. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY RESEARCH LABORATORIES & CROS, BY REGION, 2025-2030 (USD MILLION)
  • TABLE 61. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 62. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 63. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 64. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 65. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 66. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 67. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 68. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 69. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. AMERICAS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 71. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 72. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 73. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 74. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 75. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 76. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 77. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 78. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 79. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
  • TABLE 80. UNITED STATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
  • TABLE 81. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 82. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 83. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 84. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 85. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 86. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 87. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 88. CANADA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 89. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 90. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 91. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 92. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 93. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 94. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 95. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 96. MEXICO RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 97. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 98. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 99. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 100. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 101. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 102. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 103. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 104. BRAZIL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 105. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 107. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 108. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 109. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 110. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 111. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 112. ARGENTINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 113. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 114. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 123. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 125. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 126. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 127. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 128. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 129. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 130. UNITED KINGDOM RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 131. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 132. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 133. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 134. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 135. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 136. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 137. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 138. GERMANY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 139. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 141. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 142. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 143. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 144. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 145. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 146. FRANCE RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 147. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 148. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 149. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 150. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 151. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 153. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 154. RUSSIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 155. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 156. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 157. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 158. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 159. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 161. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 162. ITALY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 163. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 164. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 165. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 166. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 167. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 169. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 170. SPAIN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 171. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 172. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 173. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 174. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 175. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 177. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 178. UNITED ARAB EMIRATES RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 179. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 181. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 182. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 183. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 185. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 186. SAUDI ARABIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 187. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 188. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 189. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 190. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 191. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 192. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 193. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 194. SOUTH AFRICA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 195. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 197. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 198. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 199. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 200. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 201. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 202. DENMARK RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 206. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 207. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 209. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 210. NETHERLANDS RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 211. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 213. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 214. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 215. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 216. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 217. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 218. QATAR RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 219. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 220. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 221. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 222. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 223. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 225. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 226. FINLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 227. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 228. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 229. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 230. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 231. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 233. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 234. SWEDEN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 235. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 236. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 237. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 238. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 239. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 241. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 242. NIGERIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 243. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 245. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 246. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 247. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 249. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 250. EGYPT RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 251. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 253. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 254. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 255. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 256. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 257. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 258. TURKEY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 259. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 260. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 261. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 262. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 263. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 265. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 266. ISRAEL RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 267. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 269. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 270. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 271. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 272. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 273. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 274. NORWAY RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 275. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 276. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 277. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 278. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 279. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 281. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 282. POLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 283. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 285. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 286. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 287. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 288. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 289. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 290. SWITZERLAND RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 299. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 300. ASIA-PACIFIC RARE DISEASE DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
  • TABLE 301. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 302. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 303. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 304. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 305. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 307. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 308. CHINA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 309. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 311. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 312. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 313. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 314. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 315. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 316. INDIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 317. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 318. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 319. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 320. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 321. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2025-2030 (USD MILLION)
  • TABLE 323. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2018-2024 (USD MILLION)
  • TABLE 324. JAPAN RARE DISEASE DIAGNOSTICS MARKET SIZE, BY END-USER, 2025-2030 (USD MILLION)
  • TABLE 325. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
  • TABLE 326. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
  • TABLE 327. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
  • TABLE 328. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
  • TABLE 329. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SIZE, BY DISEASE TYPE, 2018-2024 (USD MILLION)
  • TABLE 330. AUSTRALIA RARE DISEASE DIAGNOSTICS MARKET SI